Health economics for treatment of diabetic foot ulcers: a cost-effectiveness analysis of eight skin substitutes
- PMID: 31509489
- DOI: 10.12968/jowc.2019.28.Sup9.S14
Health economics for treatment of diabetic foot ulcers: a cost-effectiveness analysis of eight skin substitutes
Abstract
Aim: Skin substitutes are frequently used to treat chronic diabetic foot ulcers (DFU), and many different options are available. While the clinical efficacy of many products has been evaluated, a comprehensive cost-effectiveness analysis comparing the most popular skin substitutes and using the most recent cost data has been lacking.
Methods: This study compared eight skin substitutes using published efficacy rates combined with the Centers for Medicare and Medicaid Services (CMS) 2018 cost data. The study criteria resulted in the inclusion of seven studies that described efficacy rates for treatment of DFUs using the skin substitutes.
Results: The results revealed wide discrepancies between these skin substitutes for the costs of treatments and healing rates in hospital outpatient departments and physician office settings. Healing rates for 12 and 16 weeks ranged from 28% to 68%, while the average cost for treating one DFU varied from $2001 to $14,507 and $1207 to $8791 in the hospital outpatient department and physician's office setting, respectively. The estimated patient share of costs for treating a single DFU ranged from $400 to $2901 and $241 to $1758 in the hospital outpatient department and physician's office setting, respectively. Most importantly, the estimated number of wounds healed out of 100 DFUs per $1000 expenditure with each patient ranged from 3.9-26.5 DFUs in the hospital outpatient department, and 4.3-36.4 DFUs in the physicians' office setting.
Conclusions: This study revealed that the costs of a skin substitute itself did not necessarily correlate with its healing efficacy. These results provide a comprehensive cost-effectiveness analysis to enable integrated health-care systems, health professionals and reimbursement payers to make informed value decisions when treating DFUs.
Keywords: cost-effectiveness; diabetic foot ulcer; economics; skin substitute; treatment efficacy.
Similar articles
-
A comparative analysis of skin substitutes used in the management of diabetic foot ulcers.J Wound Care. 2016 Oct 1;25(Sup10):S8-S17. doi: 10.12968/jowc.2016.25.Sup10.S8. J Wound Care. 2016. PMID: 27681811
-
Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers.J Med Econ. 2015;18(8):586-95. doi: 10.3111/13696998.2015.1031793. Epub 2015 Apr 22. J Med Econ. 2015. PMID: 25786331
-
The cost effectiveness of Apligraf treatment of diabetic foot ulcers.Pharmacoeconomics. 2003;21(16):1171-83. doi: 10.2165/00019053-200321160-00003. Pharmacoeconomics. 2003. PMID: 14594438
-
Evidence for Healing Diabetic Foot Ulcers With Biologic Skin Substitutes: A Systematic Review and Meta-Analysis.Ann Plast Surg. 2019 Oct;83(4S Suppl 1):S31-S44. doi: 10.1097/SAP.0000000000002096. Ann Plast Surg. 2019. PMID: 31513064
-
Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers.BioDrugs. 2002;16(6):439-55. doi: 10.2165/00063030-200216060-00005. BioDrugs. 2002. PMID: 12463767 Review.
Cited by
-
Tissue Engineering-Based Strategies for Diabetic Foot Ulcer Management.Adv Wound Care (New Rochelle). 2023 Mar;12(3):145-167. doi: 10.1089/wound.2021.0081. Epub 2021 Dec 22. Adv Wound Care (New Rochelle). 2023. PMID: 34939837 Free PMC article. Review.
-
Wound dressings: curbing inflammation in chronic wound healing.Emerg Top Life Sci. 2021 Oct 29;5(4):523-537. doi: 10.1042/ETLS20200346. Emerg Top Life Sci. 2021. PMID: 34196717 Free PMC article. Review.
-
A multicenter, randomized controlled clinical trial evaluating the effects of a novel autologous heterogeneous skin construct in the treatment of Wagner one diabetic foot ulcers: Final analysis.Int Wound J. 2023 Dec;20(10):4083-4096. doi: 10.1111/iwj.14301. Epub 2023 Jul 4. Int Wound J. 2023. PMID: 37402533 Free PMC article. Clinical Trial.
-
Reactive oxygen species-degradable polythioketal urethane foam dressings to promote porcine skin wound repair.Sci Transl Med. 2022 Apr 20;14(641):eabm6586. doi: 10.1126/scitranslmed.abm6586. Epub 2022 Apr 20. Sci Transl Med. 2022. PMID: 35442705 Free PMC article.
-
A novel intervention for wound bed preparation in severe extremity trauma: Highly concentrated carbon dioxide bathing.JPRAS Open. 2024 May 31;41:88-97. doi: 10.1016/j.jpra.2024.05.011. eCollection 2024 Sep. JPRAS Open. 2024. PMID: 38979443 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical